
What is Claimed is:

1. A cancer chemotherapeutic agent comprising, in combination, a cholestanol derivative represented by formula (1):



(1)

(wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof, and an anti-cancer agent.

2. A cancer chemotherapeutic agent according to claim 1, wherein, in formula (1), G is GlcNAc-Gal- or GlcNAc-.

3. A cancer chemotherapeutic agent according to claim 1 or 2, wherein the anti-cancer agent is one or more species selected from the group consisting of a taxane anti-cancer agent, a platinum complex anti-cancer agent, a pemetrexed compound, and fluorouracil.

4. A cancer chemotherapeutic agent according to claim 3, wherein the anti-cancer agent is one or more species selected from the group consisting of Paclitaxel, Docetaxcel, Alimta, 5-FU, Cisplatin, and Oxaliplatin.


5. A cancer chemotherapeutic agent according to any of claims 1 to 4, which is a compounding agent.

6. A cancer chemotherapeutic agent according to any of

claims 1 to 4, which is in the form of a kit including a drug containing a cholestanol derivative and a drug containing an anti-cancer agent.

7. A cancer chemotherapeutic agent according to claim 6, wherein the drug containing a cholestanol derivative is a liposomal formulation.


8. Use, in combination, of a cholestanol derivative represented by formula (1):



(1)

(wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof and an anti-cancer agent, for producing a cancer chemotherapeutic agent.

9. A cancer chemotherapy, characterized by comprising administering, in combination, a cholestanol derivative represented by formula (1):



(1)


(wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof and an anti-cancer agent, to a patient in need thereof.

10. A cancer chemotherapy according to claim 9, wherein the cholestanol derivative or a cyclodextrin inclusion compound thereof and the anti-cancer agent are administered to a patient in need thereof simultaneously, or separately and intermittently.

Claims

1. A cancer chemotherapeutic agent comprising, in combination,

   (a) a cholestanol derivative represented by formula (1) :



(1)

   (wherein G is GlcNAc-Gal- or GlcNAc-) or a cyclodextrin inclusion compound thereof; and
   (b) an anti-cancer agent.

2. A cancer chemotherapeutic agent according to claim 1, wherein the anti-cancer agent is one or more species selected from the group consisting of a platinum complex anti-cancer agent.


3. A cancer chemotherapeutic agent according to claim 2, wherein the anti-cancer agent is one or more species selected from the group consisting of Cisplatin and Oxaliplatin.

4. A cancer chemotherapeutic agent according to any of claims 1 to 3, which is a compounding agent.

5. A cancer chemotherapeutic agent according to any of claims 1 to 3, which is in the form of a kit including a drug containing a cholestanol derivative and a drug containing an anti-cancer agent.

6. A cancer chemotherapeutic agent according to claim 5, wherein the drug containing a cholestanol derivative is a liposomal formulation.

7. Use, in combination, of a cholestanol derivative represented by formula (1):



(1)

(wherein G is GlcNAc-Gal- or GlcNAc-) or a cyclodextrin inclusion compound thereof and an anti-cancer agent, for producing a cancer chemotherapeutic agent.